Last $5.25 USD
Change Today +0.15 / 2.94%
Volume 236.5K
SNSS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 3:19 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

sunesis pharmaceuticals inc (SNSS) Snapshot

Open
$5.17
Previous Close
$5.10
Day High
$5.30
Day Low
$5.07
52 Week High
03/5/14 - $7.49
52 Week Low
02/5/14 - $3.84
Market Cap
315.5M
Average Volume 10 Days
755.5K
EPS TTM
$-0.71
Shares Outstanding
60.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUNESIS PHARMACEUTICALS INC (SNSS)

Related News

No related news articles were found.

sunesis pharmaceuticals inc (SNSS) Related Businessweek News

No Related Businessweek News Found

sunesis pharmaceuticals inc (SNSS) Details

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company’s lead product candidate is vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia or AML. It has completed a Phase III, randomized, double-blind, placebo-controlled, and pivotal clinical trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AMl. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of PDK1. The company was founded in 1998 and is headquartered in South San Francisco, California.

32 Employees
Last Reported Date: 03/6/14
Founded in 1998

sunesis pharmaceuticals inc (SNSS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $431.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $367.5K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $338.3K
Compensation as of Fiscal Year 2012.

sunesis pharmaceuticals inc (SNSS) Key Developments

Sunesis Pharmaceuticals, Inc. Announces Presentation of Positive Results from Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS

Sunesis Pharmaceuticals, Inc. announced the presentation of results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The results will be presented at the Phase II/III Clinical Trials Poster Session of the American Association for Cancer Research Annual Meeting 2014 (AACR) in San Diego, California. The poster (Poster #7, Hall A-E, Poster Section 38) is titled "Phase I/II study of vosaroxin and decitabine in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)." The Phase 1b/2 trial is expected to enroll up to a combined total of approximately 70 patients. As previously announced, the Phase 2 cohort of the Phase 1b/2 was initiated in October 2013, following successful completion of a Phase 1b open-label, single-arm dose optimization phase. Patients in the ongoing trial are being followed for rate of response, leukemia-free survival, overall survival and safety. To date, the combination of vosaroxin and decitabine has been found to be effective and well tolerated in older patients with AML and high-risk MDS. Twenty four patients are evaluable for response; 9 (38%) achieved complete response (CR), 5 (21%) achieved CR with incomplete platelet recovery (CRp), and 2 (8%) achieved CR with incomplete peripheral blood count recovery (CRi), for an overall response rate of 67%. The main grade >= 3 toxicity was mucositis in 6 (6/29, 21%) patients. No patients died during the initial 30-day induction period. Enrollment in the trial is ongoing. For the trial, patients were treated with vosaroxin (90 mg/m(2)) intravenously on days one and four in combination with decitabine (20 mg/m(2)) on days one to five. Vosaroxin dose was reduced to 70 mg/m(2) in consolidation cycles, which were repeated in approximately four to five week intervals for a total of up to seven cycles. Dose adjustments and dose delays of one or both agents were allowed based on toxicity. Patients were eligible if they had AML or high-risk MDS (defined as having >= 10% blasts in the bone marrow), were 60 years of age or older, and had adequate performance status (ECOG <= 2) and organ function. Patients younger than 60 who were unsuited for standard chemotherapy were also eligible. The primary endpoint of the study is to determine the CR rate. Secondary endpoints include CR duration, disease-free survival, overall survival, safety and early mortality. To date, 29 patients (25 AML, 4 high-risk MDS) with a median age of 73 years (range, 41-78) have been enrolled; 97% were older than 60 years and 59% were older than 70 years. Of these, 24 patients were evaluable for response; 9 (38%) achieved CR, 5 (21%) achieved CRp, and 2 (8%) achieved CRi, for an overall response rate of 67%. One patient without a response after cycle one is currently undergoing re-induction. Five patients are too early for response assessment. Patients have received a median of 2 (1-6) treatment cycles with median number of cycles to response being 1 (1-4). The regimen was found to be well tolerated. The main grade >= 3 toxicity was mucositis in 6 (6/29, 21%) patients. No patients died during the initial 30-day induction period.

Sunesis Pharmaceuticals, Inc. - Special Call

To discuss phase I/II study of vosaroxin and decitabine in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome

Sunesis Pharmaceuticals, Inc. Reports Consolidated Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Sunesis Pharmaceuticals, Inc. reported consolidated unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total revenues of $1,989,000 compared with $1,989,000 for the same period last year. Loss from operations was $7,592,000 compared with $8,073,000 for the same period last year. Net loss was $7,177,000 or $0.15 diluted per share compared with $4,052,000 or $0.20 diluted per share for the same period last year. Cash used in operations was $9.7 million as compared to $9.3 million for the same periods in 2012. For the full year, the company reported total revenues of $7,956,000 compared with $3,754,000 for the same period last year. Loss from operations was $31,773,000 compared with $34,606,000 for the same period last year. Net loss was $34,598,000 or $0.66 diluted per share compared with $43,951,000 or $0.91 diluted per share for the same period last year. Revenue in both years was due to deferred revenue recognized under the royalty agreement with Royalty Pharma. Cash used in operations was $37.4 million as compared to $10.6 million for the same periods in 2012. Net cash used in resulted primarily from the net loss of $34.6 million and changes operating assets and liabilities of $7.1 million, including $8.0 related to recognition of deferred revenue under the royalty agreement with Royalty Pharma, partially offset by net adjustments for non-cash items of $4.3 million, including expenses of $3.9 million related stock-based compensation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNSS:US $5.24 USD +0.14

SNSS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $7.26 USD +0.13
NeurogesX Inc $0.0068 USD -0.0001
Pozen Inc $8.61 USD +0.14
View Industry Companies
 

Industry Analysis

SNSS

Industry Average

Valuation SNSS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 31.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUNESIS PHARMACEUTICALS INC, please visit www.sunesis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.